Applications And Challenges Of Titanium Alloys in Cardiovascular Implantation

Cardiovascular diseases remain a leading cause of mortality worldwide, and interventional implantable devices serve as a critical therapeutic approach for a wide range of cardiovascular disorders. The comprehensive performance of implant materials dictates long-term treatment outcomes. Titanium alloys  boast outstanding overall properties and have become the primary substrate for cardiac stents, total artificial hearts and other devices. Nevertheless, drawbacks including poor blood compatibility, mismatched mechanical properties and inadequate surface performance hinder technological advancement of high-end cardiovascular implant devices.

1.Excellent biocompatibility and corrosion resistance

A stable titanium dioxide passivation film forms on the material surface, resisting corrosion by body fluids and preventing heavy metal ion leaching. This reduces inflammation, immune rejection and infection, facilitates endothelial cell proliferation, and meets the requirements for long-term implantation.

2.Mechanical properties matching physiological vasculature

Titanium alloys feature high specific strength and low weight. Beta-type titanium alloys possess an elastic modulus close to that of human blood vessels, alleviating stress shielding and vascular irritation. Nickel-titanium alloys exhibit shape memory and superelasticity, making them ideal for minimally invasive interventional procedures.

3.Favourable clinical applicability

Titanium alloys are MRI-compatible, allowing implanted patients to undergo routine magnetic resonance imaging. They deliver clear radiographic visibility to support precise intraoperative manipulation and improve surgical safety.

1.Coronary and peripheral vascular stents

This represents the dominant application of titanium alloys. Titanium stents outperform stainless steel alternatives in flexibility and lower the risk of vascular restenosis. Self-expanding nickel-titanium memory alloy stents can be crimped for minimally invasive delivery and conform to complex vascular anatomies. Mainstream drug-eluting stents release therapeutic agents via coatings to inhibit vascular hyperplasia. Stents with biodegradable coatings retain a titanium load-bearing framework while the coating gradually degrades, yielding superior long-term clinical performance.

2.Artificial hearts and ventricular assist devices (VADs)

Ti-6Al-4V alloy demonstrates exceptional fatigue resistance and anti-haemolytic properties, rendering it the preferred material for pump housings and impellers in devices treating end-stage heart failure. For instance, the SynCardia total artificial heart relies on a titanium alloy main body to sustain stable blood pumping, providing long-term circulatory support for patients awaiting heart transplantation.

3.Components for heart valves and pacing devices

Titanium alloy frames for artificial heart valves strike a balance between light weight and deformability compatible with the valve annulus, mitigating regurgitation and inflammatory risks. The alloy is also utilised for the outer casings and bases of pacemakers and implantable cardioverter-defibrillators (ICDs). Its corrosion resistance and low magnetic susceptibility enable permanent implantation alongside full MRI compatibility.

4.Surgical repair materials for cardiac procedures

Titanium sheets and meshes are deployed for sternal fixation, tissue defect repair and vascular reconstruction. Their light weight and sufficient mechanical strength accommodate dynamic movements of the heart and thoracic cage, lowering postoperative complication rates.

1.Insufficient blood compatibility

The titanium matrix exhibits low biological activity, readily triggering thrombosis, chronic inflammation and haemolysis. Patients are therefore required to receive long-term anticoagulant therapy post-surgery, which carries inherent bleeding risks.

2.Imperfect mechanical matching

Titanium alloys have a higher elastic modulus than native blood vessels, resulting in stress shielding that impairs vascular repair. Conventional titanium alloys possess limited ductility and are prone to fatigue damage under prolonged cyclic loading, failing to satisfy manufacturing demands for

precision micro-devices.

3.Limitations of surface modification technologies

Drug coatings and diamond-like carbon (DLC) coatings are prone to delamination with short drug efficacy durations. Modification processes incur high production costs while compromising the substrate's mechanical performance, restricting large-scale industrial adoption.

4.Deficiencies under specialised service conditions

Aluminium and vanadium contained in traditional titanium alloys carry potential risks of ion elution. The materials pose processing challenges when fabricating ultra-fine and ultra-thin micro-components, and their radiographic visibility is inferior to that of precious metals, impeding microsurgical operations on tiny blood vessels and imaging follow-ups.

1.Advanced alloy design

High-purity aluminium-vanadium-free beta titanium alloys will emerge as mainstream materials. Alloying elements such as tantalum, niobium and zirconium will be incorporated to reduce toxic risks, relieve stress shielding and enhance long-term implantation safety.

2.Multi-functional composite coatings

Bioactive composite coatings integrating anticoagulant, endothelialisation-promoting and anti-inflammatory functions will be developed. Intelligent sustained-release coatings will address coating detachment and short drug action cycles to prevent thrombosis and vascular restenosis.

3.Innovative manufacturing processes

Micro-nano machining and additive manufacturing (3D printing) will enable customised fabrication of vascular devices. Biodegradable titanium composites will balance mechanical support with controllable post-operative degradation.

4.Intelligent implant devices

Leveraging titanium alloys' unique mechanical and conductive properties, smart implantable systems will be developed to continuously monitor multiple vascular biomarkers, underpinning precision clinical cardiovascular treatment.